Already in 2008, the United States Adult Cystic Fibrosis Association Inc. President Laura Tillman writes that 'Anti-Pseudomonas IgY has great potential to prevent P. aeruginosa infections.' SInce then this clinial study has moved forward to a phase III! Press HERE to follow the link!


'Interesting' earlier scientific articles:


Project Dissemination - Results



  • Manuscript (in press):
    Thomsen K, ChristophersenL , BjarnsholtT , JensenP 0, MoserC ,H oiby N.
    Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine
    pneumonia model.
    Manuscript in press to Journal of Cystic Fibrosis.
  • Manuscript (submitted):

    Thomsen K, Christophersen L, Jensen P0, Bjarnsholt T , Moser C ,Hoiby N.
    Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.
    Manuscripts submitted to Clinical and ExperimentaI lmmunology.

  • The results of the Lithuanian group (WP5) have led to a submitted manuscript:”Anti-Pseudomonas aeruginosa IgY do not change bacterial flora and epithelial cells of gastrointestinal tissue in mice”.

Dissemination Activities

  • Web page of the State Research Institute Centre for Innovative Medicine,
  • A production and application of IgY as a medicinal product was announced at conference   organized by Lithuanian society for immunology dedicated for International  Day  of Immunology 2015 April 29.
  • POSTER: 'Twenty years of clinical studies on Anti- Pseudomonas IgY to Cystic Fibrosis patients', by Hans Kollberg at the ECFS meeting,10-13 JUNE 2015


As the contact point for clinical trial participants: All national CF patient associations of the EU countries are a member of CF Europe. That means CFE is in contact with the national CF associations of all partner-countries of this project. Each year those associations are updated about the study and about CFE’s role in the study at least 1 time, during CFE’s general meeting. Thus, CFE is the contact point for CF associations contact us in case they have questions about the project or about the involvement of patients in clinical trial in general and we give them tailor-made information and support where and when needed.

• The CFE websites & Facebook page: CFE’s own website ( and the wikiCF website ( spread information on the project to the European CF community and beyond. Here yiu can find a call launched  for patients to take part in the study.



Dissemination Activities

  • Flyers by Partner VALSTYBINIS MOKSLINIU TYRIMU INSTITUTAS INOVATYVIOS MEDICINOS CENTRAS 'Toxicity studies - Anti-Pseudomonas IgY' -  06/07/2014 Annual Scientific Conference of the State Research Institute Centre for Innovative Medicine 6-7.12.2
  • Web sites/Applications by Partner VALSTYBINIS MOKSLINIU TYRIMU INSTITUTAS INOVATYVIOS MEDICINOS CENTRAS Cystic fibrosis clinical research in the treatment of Pseudomonas IgY immunoglobulin A." Immunoglobulin IgY Pseudomonas A Clinical Trial for Cystic Fibrosis Treatment (IMPACTT) (2010 to 2014) 01/01/2014


CFE provides a wide communication about the project to the CF community and the wide public, through oral presentations:

  • To all national CF patient organisations, during the annual meeting of CFE in Gothenburg in 2014.-
  • At the South Eastern European CF conference in Thessaloniki in October 2014 for patients & health care professionals from more than 10 countries.
  • During meetings of the cystic fibrosis patient organisations involved in research: In January 2014 this took place in Leuven (BE), in January 2015 there was a meeting in Barcelona (ES). Patient representatives, experts in research from 7 countries participate in this meeting. CFE updates them bi-annually on the research work done on the European level.o Contacts with CF specialists and patients during different meetings and conferences-
  • At the ECFS conference in Goteborg, Sweden in June 2014- The ERS (European Respiratory Society) Congress in Germany in September 2014- The South Eastern European CF conference in Thessaloniki Greece in October 2014










News in German: